Zealand and Generate in 1.2B AI Obesity Drug Deal
Zealand Pharma partnered with Generate Biomedicines to develop AI driven obesity treatments in a deal worth up to 1.2 billion dollars. Generate will lead early research while Zealand handles clinical development and commercialization.
Xurve View
Insights:
Xurve View
Zealand Pharma A/S partnered with Generate Biomedicines to develop AI-driven protein treatments for obesity in a deal worth up to $1.2B. The agreement taps artificial intelligence to build multispecific therapies targeting multiple metabolic pathways simultaneously. The collaboration positions Zealand to expand its obesity pipeline beyond blockbuster treatments offered by Novo Nordisk A/S-B and Eli Lilly & Co to capture shifting market demand.
